ACHV

Business Context and Reporting Period

Company: OncoGenex Pharmaceuticals, Inc. (formerly Sonus Pharmaceuticals, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2010
Business Overview: OncoGenex is a clinical-stage biopharmaceutical company focused on developing cancer therapies that address treatment resistance. The company's pipeline includes five candidates: custirsen (lead asset), OGX-427, OGX-225, SN2310, and CSP-9222. In December 2009, the company entered a strategic Collaboration Agreement with Teva Pharmaceutical Industries Ltd. for the global development and commercialization of custirsen.

Key Financial Metrics

Debt and Liquidity: The company has no borrowing or credit facilities. As of December 31, 2010, the company held $85.1 million in cash and short-term investments. Management believes these resources are sufficient to fund operations into 2014.

Material Changes vs. Prior Period

• Revenue Decline: Collaboration revenue decreased by approximately 47% from $25.5 million in 2009 to $13.6 million in 2010. This decrease is due to the recognition of the upfront payment from Teva in 2009, with 2010 revenue reflecting amortization of the remaining deferred revenue and reimbursable costs.
• Increased Net Loss: Net loss widened to $12.6 million in 2010 from $5.5 million in 2009. This was driven by a $4.0 million restructuring expense related to excess facility lease liabilities and increased general and administrative costs, partially offset by a $3.0 million income tax recovery.
• Restructuring Charges: A $4.0 million charge was recorded in September 2010 due to revised sublease income assumptions for the company's Bothell, Washington facility.
• Capital Raise: In October 2010, the company completed a public offering raising $46.7 million in net proceeds, significantly increasing cash reserves.

Guidance, Outlook, and Risks

Clinical Development Outlook:

• Custirsen: Two Phase 3 trials in metastatic castrate-resistant prostate cancer (CRPC) are ongoing (SATURN and SYNERGY). A third Phase 3 trial in non-small cell lung cancer (NSCLC) is expected to initiate in 2011.
• OGX-427: A Phase 2 trial in CRPC is ongoing. A Phase 2 trial in metastatic bladder cancer is expected to initiate in the second half of 2011.
• Other Assets: SN2310 is being explored for out-licensing. OGX-225 and CSP-9222 remain in pre-clinical development.

Management Commentary: The company expects to continue incurring increasing losses as it advances its clinical programs. The collaboration with Teva provides committed funding for custirsen development, with Teva responsible for all costs beyond OncoGenex's $30 million contribution (of which $21.6 million remains to be spent).

Key Risks:

• Regulatory Approval: No products have been approved for commercial sale; success depends on Phase 3 trial results and FDA/EMA approval.
• Dependence on Teva: The company relies heavily on Teva for the commercialization and majority of funding for its lead asset, custirsen.
• Financing: While cash is sufficient through 2014, future capital requirements may necessitate additional equity or debt financing, which could be dilutive.
• Manufacturing: The company relies entirely on third-party contract manufacturers.

Investor Verification Checklist

• Phase 3 Trial Progress: Verify enrollment rates and interim data for the SATURN and SYNERGY trials for custirsen.
• Cash Burn Rate: Monitor quarterly cash usage to confirm the runway extends into 2014 as projected.
• Teva Collaboration Status: Confirm Teva's continued commitment and funding disbursements under the Clinical Development Plan.
• Restructuring Liability: Track the resolution of the $7.5 million excess facility lease liability and potential sublease income.
• Out-licensing of SN2310: Assess progress in finding a partner for the SN2310 asset to generate potential milestone revenue.